---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-071942"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:44:48.603424+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cabaletta Bio Q4 2022: cash $106.5M, CABA-201 IND expected H1 2023, data H1 2024

## Summary
- R&D expenses $12.4M (Q4) and $39.3M (FY2022), up from $9.9M and $32.5M YoY.
- Cash and investments $106.5M at Dec 31, 2022; funding expected into Q1 2025.
- CABA-201 IND clearance expected H1 2023; initial clinical data anticipated H1 2024.
- Raised $32.6M net in December 2022 public offering of pre-funded warrants and common stock.
- DSG3-CAART combination sub-study data (1-month) expected H1 2023; MuSK-CAART trial initiated Nov 2022.

## SEC filing metadata
- accession: 0001193125-23-071942
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000119312523071942/0001193125-23-071942-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000119312523071942/d409494d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-071942
- JSON: https://secwatch.observer/filing/0001193125-23-071942.json
- Plain text: https://secwatch.observer/filing/0001193125-23-071942.txt

## Key facts
- Earnings Releases
  Cabaletta Bio, Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2022.
  - Period: fourth quarter and fiscal year ended December 31, 2022
  - Result: reported results
  source text: On March 16, 2023, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the fourth quarter and fiscal year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759138/000119312523071942/0001193125-23-071942-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.